Thomas Herzog, MD, University of Cincinnati

Articles by Thomas Herzog, MD, University of Cincinnati

Thomas Herzog, MD, deputy director, University of Cincinnati Cancer Center, member, Board of Directors, Gynecologic Oncology Group (GOG) Foundation, associate director, GOG Partners

Dr. Herzog on the FDA Approval of Mirvetuximab Soravtansine in FRα–positive Gynecologic Cancers

ByThomas Herzog, MD, University of Cincinnati

February 6th 2023

Thomas Herzog, MD, discusses how the recent FDA approval of the novel antibody-drug conjugate mirvetuximab soravtansine-gynx ameliorates unmet need in platinum-resistant, folate receptor alpha–positive gynecological cancers.

Thomas Herzog, MD, University of Cincinnati

Articles by Thomas Herzog, MD, University of Cincinnati

Dr. Herzog on the FDA Approval of Mirvetuximab Soravtansine in FRα–positive Gynecologic Cancers

Latest Updated Articles

Trending on OncLive

Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma

Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer

Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies

FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma

Oncology Fellows Highlights 2025 ESMO Fellowship Winners